PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells

Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor “programmed-cell-death-1” (PD1) and its ligand (PD-L1), because most cases lack the required mutational burden and neo-antigen load caused by micros...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutting, Tobias, Hauber, Veronika, Pahl, Jens, Klapproth, Kay, Wu, Wenyue, Dobrota, Ioana, Herweck, Frank, Reichling, Juliane, Helm, Laura, Schroeder, Torsten, Li, Beifang, Weidner, Philip, Zhan, Tianzuo, Eckardt, Maximilian, Betge, Johannes, Belle, Sebastian, Sticht, Carsten, Gaiser, Timo, Boutros, Michael, Ebert, Matthias P.A., Cerwenka, Adelheid, Burgermeister, Elke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115557/
https://www.ncbi.nlm.nih.gov/pubmed/34026331
http://dx.doi.org/10.1080/2162402X.2021.1906500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115557/
https://www.ncbi.nlm.nih.gov/pubmed/34026331
http://dx.doi.org/10.1080/2162402X.2021.1906500

Ejemplares similares